Program
ivonescimab
Also written as “AK112”, “Ivonescimab” and “Ivonescimab Injection”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Ovarian Neoplasms · Triple Negative Breast Neoplasms · Small Cell Lung Carcinoma, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akeso | 3930 open or running | phase 3since Dec 21, 2021 | Aug 5, 2019 | Dec 2026phase 2 · NCT05689853 |
| Summit Therapeutics | 66 open or running | phase 3since Jun 1, 2023 | Jun 1, 2023 | Apr 2028phase 3 · NCT06767514 |
| GlaxoSmithKline | 11 open or running | phase 2since May 15, 2026 | May 15, 2026 | Jun 22, 2029phase 2 · NCT07602855 |
| Multitude Therapeutics | 11 open or running | phase 2since May 10, 2026 | May 10, 2026 | May 30, 2027phase 2 · NCT07590531 |
| Shanghai Allink Biotherapeutics | 11 open or running | phase 2since Jul 29, 2026 | Jul 29, 2026 | Dec 31, 2027phase 2 · NCT07742956 |
Also a collaborator on its studies: shanghai-virogin-biotech-co-ltd.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseSummit Therapeutics licensed it from Akeso, for the US, Canada, Europe and Japan.Announced Dec 6, 2022 · Source: Summit Therapeutics (8-K exhibit), Dec 6, 2022
How GlaxoSmithKline, Multitude Therapeutics and Shanghai Allink Biotherapeutics relate to it is not in the registry or these sources.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 31 studies since Aug 5, 2019.
- Mar 10, 2025Phase 2 study in Biliary Tract NeoplasmsAkeso · NCT06938321 · 135 planned · China
- Apr 8, 20253 phase 3 studiesAkeso · NCT06928389, NCT06951503, NCT06953999
- May 25, 2025Phase 3 study in Small Cell Lung CarcinomaAkeso · NCT07010263 · 560 planned · China
- Aug 3, 20252 phase 2 studiesAkeso · NCT07114315, NCT07158840
- Sep 29, 2025Phase 2 study in Small Cell Lung CarcinomaAkeso · NCT07245446 · 180 planned · China
- Nov 10, 2025Phase 3 study in Colorectal NeoplasmsSummit Therapeutics · NCT07228832 · 900 planned · United States, Belgium, Canada and more
- Dec 24, 2025Phase 2 study in Colorectal Cancer With Hepatic MetastasesAkeso · NCT07357220 · 72 planned · China
- Jan 6, 2026Phase 1 study in Healthy Male SubjectsAkeso · NCT07340476 · 108 enrolled · China
- May 10, 2026Multitude Therapeutics's first study: phase 2 study in Advanced Non-small Cell Lung Cancer (NSCLC)New to Multitude TherapeuticsMultitude Therapeutics · NCT07590531 · 118 planned · China
- May 15, 2026GlaxoSmithKline's first study: phase 2 study in Lung NeoplasmsNew to GlaxoSmithKlineGlaxoSmithKline · NCT07602855 · 184 planned · United States, Japan
- Jun 21, 2026Phase 2 study in Advanced Non Small Cell Lung Cancer (NSCLC)Akeso · NCT07669779 · 348 planned · China
- Jul 29, 2026Shanghai Allink Biotherapeutics's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Shanghai Allink BiotherapeuticsShanghai Allink Biotherapeutics · NCT07742956 · 156 planned
- Aug 31, 2026Phase 3 study in Carcinoma, Transitional CellSummit Therapeutics · NCT07815665 · 800 planned · United States
- Sep 29, 2026Phase 2 study in Carcinoma, Renal CellSummit Therapeutics · NCT07877194 · 100 planned · United States, China
Ahead
- Dec 2026Primary completion: phase 3 study in Triple Negative Breast NeoplasmsAkeso · NCT06767527
- Dec 2026Primary completion: phase 2 study in Solid Tumor, AdultAkeso · NCT05689853
- Dec 30, 2026Primary completion: phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaAkeso · NCT06646055
- Dec 30, 2026Primary completion: phase 2 study in Triple Negative Breast NeoplasmsAkeso · NCT05227664
TargetBeta
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tivunatamig | Pfizer | phase 3 | 15 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010 | Merck | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039Arule | Minghui Pharmaceutical | phase 2 | 3 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rule | wigen-biomedicine-technology-shanghai-co-ltd | phase 2 | 2 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rule | compass-therapeutics | phase 1 | 1 |
Studies
All 48 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07877194Carcinoma, Renal Cell · United States, China | 2 | Not yet recruiting | Summit Therapeutics | Apr 12, 2029 | 100 |
| NCT07815665Carcinoma, Transitional Cell · United States | 3 | Recruiting | Summit Therapeutics | Oct 31, 2030 | 800 |
| NCT07742956Carcinoma, Non-Small-Cell Lung | 2 | Not yet recruiting | Shanghai Allink Biotherapeutics | Dec 31, 2027 | 156 |
| NCT07669779Advanced Non Small Cell Lung Cancer (NSCLC) · China | 2 | Recruiting | Akeso | Aug 30, 2027 | 348 |
| NCT07602855Lung Neoplasms · United States, Japan | 2 | Recruiting | GlaxoSmithKline | Jun 22, 2029 | 184 |
| NCT07590531Advanced Non-small Cell Lung Cancer (NSCLC) · China | 2 | Recruiting | Multitude Therapeutics | May 30, 2027 | 118 |
| NCT07340476Healthy Male Subjects · China | 1 | Active, not recruiting | Akeso | Apr 10, 2026 | 108 |
| NCT07357220Colorectal Cancer With Hepatic Metastases · China | 2 | Not yet recruiting | Akeso | Feb 28, 2027 | 72 |
| NCT07228832Colorectal Neoplasms · United States, Belgium, Canada and more | 3 | Recruiting | Summit Therapeutics | May 31, 2028 | 900 |
| NCT07245446Small Cell Lung Carcinoma · China | 2 | Recruiting | Akeso | Dec 2027 | 180 |
| NCT07158840Carcinoma, Non-Small-Cell Lung · China | 2 | Not yet recruiting | Akeso | Sep 2028 | 60 |
| NCT07114315Pancreatic Neoplasms · China | 2 | Recruiting | Akeso | Aug 2027 | 160 |
| NCT07010263Small Cell Lung Carcinoma · China | 3 | Recruiting | Akeso | Dec 31, 2028 | 560 |
| NCT06953999Pancreatic Neoplasms · China | 3 | Recruiting | Akeso | May 14, 2027 | 999 |
| NCT06951503Colorectal Adenocarcinoma · China | 3 | Recruiting | Akeso | Jan 13, 2027 | 560 |
| NCT06928389Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Akeso | May 2027 | 536 |
| NCT06938321Biliary Tract Neoplasms · China | 2 | Recruiting | Akeso | May 2027 | 135 |
| NCT06767527Triple Negative Breast Neoplasms · China | 3 | Recruiting | Akeso | Dec 2026 | 416 |
| NCT06767514Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 3 | Recruiting | Summit Therapeutics | Apr 2028 | 780 |
| NCT06686030Platinum-sensitive Ovarian Cancer · China | 2 | Recruiting | Akeso | Oct 2027 | 150 |
| NCT06646055Metastatic Pancreatic Ductal Adenocarcinoma · China | 2 | Active, not recruiting | Akeso | Dec 30, 2026 | 110 |
| NCT06591520Biliary Tract Neoplasms · China | 3 | Active, not recruiting | Akeso | Oct 2026 | 682 |
| NCT06601335Squamous Cell Carcinoma of Head and Neck · China | 3 | Recruiting | Akeso | Jan 2027 | 510 |
| NCT06560112Ovarian Neoplasms · China | 2 | Recruiting | Akeso | May 1, 2026 | 172 |
| NCT06530251Carcinoma, Hepatocellular · China | 2 | Recruiting | Akeso | Jun 2026 | 280 |
| NCT06396065Non-Squamous Non-small Cell Lung Cancer · United States, Canada, France and more | 3 | Active, not recruiting | Summit Therapeutics | Apr 12, 2025 | 420 |
| NCT05951608Advanced Solid Tumors · China | 2 | Active, not recruiting | Akeso | May 1, 2026 | 216 |
| NCT05899608Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 3 | Active, not recruiting | Summit Therapeutics | Dec 31, 2028 | 1,600 |
| NCT05904379Advanced Non-small-cell Lung Cancer · China | 2 | Active, not recruiting | Akeso | Jun 30, 2026 | 233 |
| NCT05846867Colorectal Neoplasms · China | 2 | Active, not recruiting | Akeso | May 8, 2026 | 170 |
| NCT05840016Advanced Squamous Non Small Cell Lung Cancer · China | 3 | Active, not recruiting | Akeso | Feb 28, 2025 | 532 |
| NCT05689853Solid Tumor, Adult · China | 2 | Recruiting | Akeso | Dec 2026 | 87 |
| NCT05636267NSCLC · China | 2 | Terminated | Akeso | Feb 24, 2025 | 59 |
| NCT05499390Advanced Non-small-cell Lung Cancer · China | 3 | Active, not recruiting | Akeso | Jan 29, 2024 | 398 |
| NCT05432492Carcinoma, Hepatocellular · China | 2 | Completed | Akeso | Apr 30, 2025 | 40 |
| NCT05382442Colorectal Neoplasms · United States, China | 2 | Active, not recruiting | Akeso | May 15, 2026 | 254 |
| NCT05229497Advanced Malignant Tumors · China | 2 | Active, not recruiting | Akeso | Dec 31, 2026 | 154 |
| NCT05227664Triple Negative Breast Neoplasms · China | 2 | Active, not recruiting | Akeso | Dec 30, 2026 | 120 |
| NCT05247684Resectable Non-small Cell Lung Cancer · China | 2 | Active, not recruiting | Akeso | Aug 18, 2025 | 90 |
| NCT05214482Advanced Malignant Tumors · China | 2 | Completed | Akeso | Nov 20, 2025 | 154 |
| NCT05184712Non-Squamous Non-small Cell Lung Cancer · China | 3 | Active, not recruiting | Akeso | Mar 10, 2023 | 322 |
| NCT05116007SCLC, Extensive Stage · China | 1 | Completed | Akeso | Dec 4, 2023 | 35 |
| NCT04999605Ovarian Neoplasms · China | 2 | Terminated | Akeso | Jun 10, 2022 | 8 |
| NCT04900363Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Akeso | Jun 28, 2024 | 108 |
| NCT04870177Neoplasm Metastasis · China | 2 | Completed | Akeso | May 10, 2024 | 53 |
| NCT04736823NSCLC · China | 2 | Active, not recruiting | Akeso | Jul 2026 | 265 |
| NCT04597541Solid Tumor, Adult · China | 2 | Completed | Akeso | Mar 31, 2022 | 59 |
| NCT04047290Neoplasms · Australia | 1 | Completed | Akeso | Feb 27, 2024 | 80 |
How it is read
Names in the registry
- “AK112”, 27 entries
- “Ivonescimab”, 3 entries
- “Ivonescimab Injection”, 3 entries
- “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
- “AK112 Injection”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 14 studies
- Colorectal Neoplasms, 4 studies
- Ovarian Neoplasms, 3 studies
- Triple Negative Breast Neoplasms, 2 studies
- Small Cell Lung Carcinoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.